Clinical trial · Interventional
Proton Beam Therapy for Chordoma Patients
Phase II Evaluation of Proton Beam Therapy for Skull Base Chordoma
NCT00496119CI-TRIAL-00114674active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to learn if proton beam therapy, with or without photon beam radiation therapy, is effective in the treatment of skull base chordoma. The safety of this treatment will also be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chordoma | Chordoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Photon Beam Therapy | Radiation | — | UNRESOLVED |
| Proton Beam Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 70 Gray (Gy) Proton Beam Therapy
- description
- Participants treated to 70 cobalt Gray equivalent (CGE) only (the standard treatment).
- interventionNames
- Radiation: Proton Beam Therapy
- type
- EXPERIMENTAL
- label
- Photon Beam Therapy
- description
- Proton beam therapy combined with photon radiation therapy where combination improves final dose distribution.
- interventionNames
- Radiation: Proton Beam Therapy
- Radiation: Photon Beam Therapy
Primary outcomes (1)
- measure
- Time to Local Recurrence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically confirmed chordoma of the skull base 2. Contrast enhanced postoperative MRI (CT in case MRI is contraindicated) of the skull base obtained within 90 days of study registration 3. MDACC surgeons have determined that optimal debulking of disease has been performed. 4. Karnofsky Performance status greater than or equal to 60 5. Signed informed consent Exclusion Criteria: 1. Previous irradiation of the skull base 2. Documented evidence of disseminated metastatic disease 3. Any concurrent malignancy (other than non-melanoma skin cancers) in the last 3 years
References
Publications (0)
Data not yet available
No reference posted for this study.